{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:06:00Z","timestamp":1791043560646,"version":"4.1.0"},"reference-count":22,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Achieving an optimal balance between thrombosis prevention and bleeding risk during temporary mechanical circulatory support remains a significant clinical challenge. Effective anticoagulation management that ensures device functionality while minimizing major bleeding events should have the potential to improve short-term outcomes. Here, we report the successful use of nafamostat mesilate (NM) as an anticoagulant during Impella support in two male patients with advanced heart failure and cardiogenic shock. NM therapy resulted in improved thrombocytopenia without the occurrence of major bleeding or thrombotic events. However, NM-related hyponatremia was observed, highlighting the need for careful monitoring during its administration and further cumulative evidence to validate optimal NM therapy during temporary mechanical circulatory supports.<\/jats:p>","DOI":"10.3390\/medicina61020309","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T11:01:08Z","timestamp":1739271668000},"page":"309","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Anticoagulation with Nafamostat Mesilate During Impella Support: A Case Report"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9604-5603","authenticated-orcid":false,"given":"Makiko","family":"Nakamura","sequence":"first","affiliation":[{"name":"The Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7294-7637","authenticated-orcid":false,"given":"Teruhiko","family":"Imamura","sequence":"additional","affiliation":[{"name":"The Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Hida","sequence":"additional","affiliation":[{"name":"The Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2703-2523","authenticated-orcid":false,"given":"Toshihide","family":"Izumida","sequence":"additional","affiliation":[{"name":"The Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4765-9593","authenticated-orcid":false,"given":"Masaki","family":"Nakagaito","sequence":"additional","affiliation":[{"name":"The Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Nagura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Doi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Kinugawa","sequence":"additional","affiliation":[{"name":"The Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"827","DOI":"10.21037\/atm-20-1127","article-title":"Statistics of heart failure and mechanical circulatory support in 2020","volume":"8","author":"Bowen","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jchf.2020.09.005","article-title":"A Standardized and Comprehensive Approach to the Management of Cardiogenic Shock","volume":"8","author":"Tehrani","year":"2020","journal-title":"JACC Heart Fail."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10047-022-01328-1","article-title":"Three-year experience of catheter-based micro-axial left ventricular assist device, Impella, in Japanese patients: The first interim analysis of Japan registry for percutaneous ventricular assist device (J-PVAD)","volume":"26","author":"Toda","year":"2023","journal-title":"J. Artif. Organs Off. J. Jpn. Soc. Artif. Organs"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa2312572","article-title":"Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock","volume":"390","author":"Jensen","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1111\/jocs.15038","article-title":"Comparison of device-specific adverse event profiles between Impella platforms","volume":"35","author":"Chen","year":"2020","journal-title":"J. Card. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"154216","DOI":"10.1016\/j.jcrc.2022.154216","article-title":"The impact of temporary mechanical circulatory support strategies on thrombocytopenia","volume":"73","author":"Dwaah","year":"2023","journal-title":"J. Crit. Care"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1056\/NEJMoa2307227","article-title":"Extracorporeal Life Support in Infarct-Related Cardiogenic Shock","volume":"389","author":"Thiele","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/ccd.30588","article-title":"Thrombocytopenia with Impella: Not a HIT","volume":"101","author":"Seto","year":"2023","journal-title":"Catheter. Cardiovasc. Interv. Off. J. Soc. Card. Angiogr. Interv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijcard.2022.07.022","article-title":"Anticoagulation with nafamostat mesilate during extracorporeal life support","volume":"366","author":"Lang","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/phar.2629","article-title":"Optimizing anticoagulation for patients receiving Impella support","volume":"41","author":"Beavers","year":"2021","journal-title":"Pharmacotherapy"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1111\/aor.14276","article-title":"Use of nafamostat mesilate for anticoagulation during extracorporeal membrane oxygenation: A systematic review","volume":"46","author":"Sanfilippo","year":"2022","journal-title":"Artif. Organs"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3109\/08860220903180616","article-title":"Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage","volume":"31","author":"Yang","year":"2009","journal-title":"Ren. Fail."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1253\/circj.CJ-19-0342","article-title":"Japanese Circulation S, the Japanese Heart Failure Society Joint Working G. JCS 2017\/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure\u2014Digest version","volume":"83","author":"Tsutsui","year":"2019","journal-title":"Circ. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4266\/acc.2021.01312","article-title":"The role of nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation","volume":"37","author":"Lee","year":"2022","journal-title":"Acute Crit. Care"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s40262-022-01170-x","article-title":"Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review","volume":"61","author":"Tong","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.4103\/1673-5374.284981","article-title":"Nafamostat mesylate attenuates the pathophysiologic sequelae of neurovascular ischemia","volume":"15","author":"Ghali","year":"2020","journal-title":"Neural Regen. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/ccd.30520","article-title":"Incidence and severity of thrombocytopenia associated with use of intravascular microaxial ventricular assist devices for treatment of cardiogenic shock","volume":"101","author":"Goetz","year":"2023","journal-title":"Catheter. Cardiovasc. Interv. Off. J. Soc. Card. Angiogr. Interv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/BF03218100","article-title":"Nafamostat mesilate modulates the release of platelet-activating factor during left ventricular assistance with hemofiltration in canine heart failure","volume":"48","author":"Munakata","year":"2000","journal-title":"Jpn. J. Thorac. Cardiovasc. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/ndt\/7.9.980a","article-title":"Agranulocytosis in a haemodialysed patient induced by a proteinase inhibitor, nafamostate mesilate","volume":"7","author":"Okada","year":"1992","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/jcpt.13646","article-title":"Incidence and risk factors for hyperkalaemia in patients treated for COVID-19 with nafamostat mesylate","volume":"47","author":"Kodama","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/0306-3623(95)00072-0","article-title":"Mechanisms of hyperkalemia caused by nafamostat mesilate","volume":"26","author":"Muto","year":"1995","journal-title":"Gen. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/01.ASN.0000043900.39397.48","article-title":"Inhibition of prostasin secretion by serine protease inhibitors in the kidney","volume":"14","author":"Iwashita","year":"2003","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/2\/309\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:30:44Z","timestamp":1760027444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/2\/309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["medicina61020309"],"URL":"https:\/\/doi.org\/10.3390\/medicina61020309","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]}}}